Disease · MONDO_0019438
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NEOD001 (24 mg/kg) + Standard of Care vs Placebo + Standard of Care: deaths from any cause | 41 of 130 | 42 of 130 | 260 | NCT02312206 | Trial comparisons |
| NEOD001 (24 mg/kg) + Standard of Care vs Placebo + Standard of Care: serious adverse events | 88 of 130 | 91 of 130 | 260 | NCT02312206 | Trial comparisons |
| NEOD001 24 mg/kg vs Placebo: deaths from any cause | 3 of 66 | 6 of 63 | 129 | NCT02632786 | Trial comparisons |
| NEOD001 24 mg/kg vs Placebo: serious adverse events | 14 of 66 | 15 of 63 | 129 | NCT02632786 | Trial comparisons |
| Phase I/II, Cohort A vs Phase II, Cohort B: deaths from any cause | 2 of 48 | 7 of 35 | 83 | NCT01864018 | Trial comparisons |
Phase I/II, Cohort A vs Phase II, Cohort B: Number of Patients Experiencing a Grade 3 or Greater Adverse Event at Least Possibly Related to Treatment as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | 36 of 48 | 16 of 35 | 83 | NCT01864018 | Trial comparisons |
| Phase I/II, Cohort A vs Phase II, Cohort B: serious adverse events | 16 of 48 | 15 of 35 | 83 | NCT01864018 | Trial comparisons |
| Doxycycline (Localized Disease) vs Doxycycline (Systemic Disease): deaths from any cause | 0 of 5 | 5 of 25 | 30 | NCT02207556 | Trial comparisons |
| Doxycycline (Localized Disease) vs Doxycycline (Systemic Disease): serious adverse events | 1 of 5 | 13 of 25 | 30 | NCT02207556 | Trial comparisons |
| Melphalan vs Melphalan + Bortezomib: deaths from any cause | 1 of 2 | 1 of 1 | 3 | NCT02489500 | Trial comparisons |
| Melphalan vs Melphalan + Bortezomib: serious adverse events | 2 of 2 | 1 of 1 | 3 | NCT02489500 | Trial comparisons |
| Bone Marrow and Kidney RECIPIENT vs Bone Marrow and Kidney DONOR: deaths from any cause | 0 of 1 | 0 of 1 | 2 | NCT02158052 | Trial comparisons |
| Bone Marrow and Kidney RECIPIENT vs Bone Marrow and Kidney DONOR: serious adverse events | 1 of 1 | 0 of 1 | 2 | NCT02158052 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019438/comparisons